Have you read these stories?

A $16-bn loan book is making India's biggest private lender tense

India’s most valuable lender by market capitalization decided against proceeding with an earlier proposal to extend the employment of ...
The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| 13 July, 2020, 10:05 AM IST | E-Paper


    Selfie lovers' delight: Vivo launches V19 with dual front camera at Rs 27,990, will go on sale this week

    The device will go on sale on Friday on Vivo's e-store, and other e-commerce website - Amazon India & Flipkart.

    Vivo V19 review: Fluid, lag-free app-loading, phenomenal camera

    The smartphone comes with a Qualcomm Snapdragon 712 processor with Adreno 616...

    US-based firm leads COVID-19 vaccine race, clinical trials show promising early results: Experts

    Cautioning that a vaccine is still months, m...

    • Elisa Granato is the first volunteer in an initial group of 800 to be part of the ground-breaking trial, which is hoped will be the answer for immunisation against the deadly virus and help with the easing of lockdown measures in place to curb its rapid transmission.

      “We, at vivo India, have been aligned to the 'Make in India’ initiative since the beginning. The new logo design that will be printed on the box of all our upcoming devices reiterates our commitment to make India a manufacturing hub and reinstates our mission of being an internationally local organization”, Nipun Marya, Director-Brand Strategy, Vivo India said.

      “When markets reopen, all the major OEMs (original equipment makers) will rush to address the latency in demand by heavily incentivising both offline and online channels,” said Neil Shah, research director, Counterpoint Research.

      This is particularly important as overall demand is not expected to revive until the third quarter of 2020, said industry executives and analysts, and mobile phone firms are likely to face production and delivery challenges in both offline and online channels.

      The researchers, working in an “unprecedented” vaccine development effort to prevent COVID-19, said they have started screening healthy volunteers (aged 18-55) from Friday for their upcoming trial in the Thames Valley Region of England. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 or COVID-19 spike protein is already in production.

      India's premier medical body ICMR has said 12 clinical trial sites for the indigenous Covaxin, being developed in collaboration with the Hyderabad-based Bharat Biotech and the National Institute of Virology (NIV), have been identified.

      A comparative analysis of impact of Covid-19 on consumer sentiments in 15 countries reveals that Indians are more concerned about their physical well-being, health of their family members, making upcoming payments and as a result are delaying large purchases.

      “When the markets reopen, all the major OEMs will rush to address the latency in demand by heavily incentivizing both offline and online channels,” said Neil Shah, Research Director, Counterpoint Research. Almost all major phone brands have suspended launch of their latest offerings including Oppo Enco M31, Vivo V19, Realme Narzo and Xiaomi Mi 10 while keeping stocks on hold.

      A total of 510 healthy volunteers, aged 18 to 55, will take part in the trial. While some participants will receive the vaccine – called ChAdOx1 nCoV-19 - others will take a control injection for comparison. The trial will continue over a couple of weeks.

      TENNIS-OPEN/HIGHLIGHTS (PIX):HIGHLIGHTS-Tennis-Day six at the U.S. Open

      An experimental vaccine for the deadly MERS virus has shown positive results in animal testing, bringing researchers a step closer.

      TENNIS-OPEN/HIGHLIGHTS (PIX):HIGHLIGHTS-Tennis-Day six at the U.S. Open

    Load More...
    The Economic Times